An exploratory study on STX6, MOBP, MAPT, and EIF2AK3 and late-onset Alzheimer's disease

Both Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) are a class of neurodegenerative diseases associated with the pathologic aggregation of tau protein in the human brain. They share some clinical and pathologic characteristics. A recent genome-wide association study reported several single-nucleotide polymorphisms at the STX6, MOBP, MAPT, and EIF2AK3 in association with PSP. To explore whether these single-nucleotide polymorphisms are associated with AD risk, we conducted a case-control study to investigate the PSP-associated loci in 1592 Han Chinese subjects. Rs242557 at the MAPT locus was associated with late-onset AD (LOAD) (odds ratio [OR], 1.175; p = 0.026), which appeared to be stronger for LOAD patients with apolipoprotein E (APOE) ε4 allele (OR, 1.510), and this positive association was not changed after adjusting for age, sex, and the APOE ε4-carrier status (additive model: OR, 1.163; p = 0.036; dominant model: OR, 1.315; p = 0.010). Rs1768208 in MOBP and rs7571971 in EIF2AK3 showed association only in the APOE ε4 positive subjects, and these did not appear to be independent of APOE. As for rs1411478 in STX6, we did not explore any association with LOAD. Our exploratory analysis mainly suggests an association of MAPT with LOAD, especially in APOE ε4 carriers. Genotypes at MOBP and EIF2AK3 confer risk predominantly in APOE ε4-positive subjects, with indications of an interaction between APOE and MOBP or EIF2AK3 on AD risk.

[1]  Francis Barany,et al.  Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2 , 2000, Nature Biotechnology.

[2]  Kenneth S. Kosik,et al.  Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred , 2003 .

[3]  D W Dickson,et al.  Neuropathology of Alzheimer's disease and other dementias. , 2001, Clinics in geriatric medicine.

[4]  W. Scheper,et al.  The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. , 2009, The American journal of pathology.

[5]  Romana Höftberger,et al.  Endoplasmic Reticulum Stress Features Are Prominent in Alzheimer Disease but Not in Prion Diseases In Vivo , 2006, Journal of neuropathology and experimental neurology.

[6]  Andrew J. Lees,et al.  Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy , 2011, Nature Genetics.

[7]  Na Zhang,et al.  Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese , 2011, Brain Research.

[8]  S. Lovestone,et al.  UK Alzheimer's Disease Genetics Consortium , 1999, International journal of geriatric psychiatry.

[9]  A. Myers,et al.  Evidence suggesting that Homo neanderthalensis contributed the H2 MAPT haplotype to Homo sapiens. , 2005, Biochemical Society transactions.

[10]  I. Grundke‐Iqbal,et al.  Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration , 2007, The European journal of neuroscience.

[11]  A M Pittman,et al.  The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. , 2005, Human molecular genetics.

[12]  F. Wendler,et al.  Syntaxin 6: The Promiscuous Behaviour of a SNARE Protein , 2001, Traffic.

[13]  Hans Förstl,et al.  Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease , 2007, Molecular Psychiatry.

[14]  Reinhard Jahn,et al.  SNAREs — engines for membrane fusion , 2006, Nature Reviews Molecular Cell Biology.

[15]  John X. Morris,et al.  Haplotype-based association analysis of the MAPT locus in Late Onset Alzheimer's disease , 2007, BMC Genetics.

[16]  F. van Leuven,et al.  Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease , 2012, International journal of Alzheimer's disease.

[17]  A. Singleton,et al.  The tau H2 haplotype is almost exclusively Caucasian in origin , 2004, Neuroscience Letters.

[18]  Peter R Schofield,et al.  GSK3B polymorphisms alter transcription and splicing in Parkinson's disease , 2005, Annals of neurology.

[19]  P. Mcgeer,et al.  Tangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA , 1999, Brain Research.

[20]  R. Liem,et al.  Primary structure of high molecular weight tau present in the peripheral nervous system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[22]  A. McCallion,et al.  Myelin-Associated Oligodendrocytic Basic Protein: A Family of Abundant CNS Myelin Proteins in Search of a Function , 2006, Developmental Neuroscience.

[23]  M. Farrer,et al.  Linkage disequilibrium and association of MAPT H1 in Parkinson disease. , 2004, American journal of human genetics.

[24]  M. Bullido,et al.  A polymorphism in the tau gene associated with risk for Alzheimer's disease , 2000, Neuroscience Letters.

[25]  G. Schellenberg,et al.  High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. , 2005, Human molecular genetics.

[26]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[27]  P. Scheltens,et al.  Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline , 2007, European journal of neurology.

[28]  Margaret A. Pericak-Vance,et al.  Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants , 2012, PLoS genetics.

[29]  J. Jia,et al.  The +347 C promoter allele up-regulates MAPT expression and is associated with Alzheimer's disease among the Chinese Han , 2009, Neuroscience Letters.

[30]  I Litvan,et al.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.

[31]  D. Wei,et al.  A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[32]  A. Myers,et al.  The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts , 2007, Neurobiology of Disease.

[33]  A J Lees,et al.  Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration , 2005, Journal of Medical Genetics.

[34]  D. Pollen,et al.  Alzheimer's disease and possible gene interaction. , 1994, Science.

[35]  M. Kirschner,et al.  Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. , 1977, Journal of molecular biology.

[36]  J. Morris,et al.  Tau polymorphisms are not associated with Alzheimer's disease , 2000, Neuroscience Letters.

[37]  M. Owen,et al.  An association study of common variation at the MAPT locus with late‐onset Alzheimer's disease , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[38]  G. Schellenberg,et al.  APOE and other loci affect age‐at‐onset in Alzheimer's disease families with PS2 mutation , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[39]  Nicholas W Wood,et al.  The structure of the tau haplotype in controls and in progressive supranuclear palsy. , 2004, Human molecular genetics.